Table 3.
Biological and clinical characteristics according to AR expression.
| Variable | Value | AR |
Median AR |
||||
|---|---|---|---|---|---|---|---|
| ⩽5% | >5% | p | <80% | ⩾80% | p | ||
| Grade | G1-G2 | 21 (60%) | 127 (73.41%) | 0.110 | 60 (61.22%) | 88 (80%) | 0.003 |
| G3 | 14 (40%) | 46 (26.59%) | 38 (38.78%) | 22 (20%) | |||
| Stage | I | 13 (92.86%) | 80 (93.02%) | 1 | 37 (92.5%) | 56 (93.33%) | 1 |
| yI | 1 (7.14%) | 6 (6.98%) | 3 (7.5%) | 4 (6.67%) | |||
| II | 12 (92.31%) | 46 (76.67%) | 0.279 | 32 (80%) | 26 (78.79%) | 0.898 | |
| yII | 1 (7.69%) | 14 (23.33%) | 8 (20%) | 7 (21.21%) | |||
| III | 4 (50%) | 16 (64%) | 0.681 | 9 (52.94%) | 11 (68.75%) | 0.481 | |
| yIII | 4 (50%) | 9 (36%) | 8 (47.06%) | 5 (31.25%) | |||
| LPI infiltrate | low | 29 (82.86%) | 163 (94.22%) | 0.021 | 91 (92.86%) | 101 (91.82%) | 0.779 |
| high | 6 (17.14%) | 10 (5.78%) | 7 (7.14%) | 9 (8.18%) | |||
| Vascular invasion | absent | 12 (34.29%) | 71 (41.04%) | 0.770 | 41 (41.84%) | 42 (38.18%) | 0.611 |
| mild | 13 (37.14%) | 55 (31.79%) | 29 (29.59%) | 39 (35.45%) | |||
| diffuse | 2 (5.71%) | 11 (6.36%) | 5 (5.1%) | 8 (7.27%) | |||
| Histotype | NOS/ductal | 26 (74.29%) | 105 (60.69%) | 0.010 | 65 (66.33%) | 66 (60%) | 0.003 |
| lobular | 5 (14.29%) | 62 (35.84%) | 24 (24.49%) | 43 (39.09%) | |||
| other | 4 (11.43%) | 6 (3.47%) | 9 (9.18%) | 1 (0.91%) | |||
| ki67 | <20% | 19 (54.29%) | 129 (74.57%) | 0.016 | 59 (60.2%) | 89 (80.91%) | 0.001 |
| ⩾20% | 16 (45.71%) | 44 (25.43%) | 39 (39.8%) | 21 (19.09%) | |||
AR, androgen receptor; LPI, lymphoplasmacytic infiltrate; NOS, not otherwise specified; value, value that the variable assumes; variable, analyzed variable; yI – yII – yIII, patients who performed neoadjuvant treatment.
Variables’ distribution within AR category is described by absolute and relative frequency (%).